Solara Active Pharma Sciences Ltd (SOLARA) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported its highest revenue, gross margins, and EBITDA in the last eight quarters, indicating a significant turnaround and operational momentum.
- The strong performance was primarily driven by the 'base business', which continues to gain traction and demonstrates superior profitability with a 26% EBITDA margin and 54% gross margin.
- The Ibuprofen business remains a major challenge, recording a negative EBITDA and prompting the board to appoint bankers to evaluate strategic options, with a decision expected in H1 FY27.
- The company has successfully reduced its debt by INR 158 crores in FY26, a 21% reduction, through a combination of rights issue proceeds and operational cash flows.
- Management has shifted its focus from a 'reset' phase to achieving sustainable, profitable, and reliable growth, emphasizing operational efficiency and leveraging existing capacities.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.